(Total Views: 404)
Posted On: 05/20/2021 9:43:02 AM
Post# of 148903
Our turn next!
Brazilian Health Regulatory Agency authorizes Sorrento's phase 2 COVID-19 trial
May 20, 2021 9:17 AM ETSorrento Therapeutics, Inc. (SRNE)By: Aakash Babu, SA News Editor
Sorrento Therapeutics (NASDAQ:SRNE) announces receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC, an injectable infusion of mesenchymal stem cells, for the treatment of hospitalized COVID-19 patients suffering from ARDS.
The study is expected to enroll 100 patients (33 placebo and 67 treated patients) in three months from the date of first enrollment.
It will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients hospitalized due to acute respiratory distress syndrome (ARDS).
Sorrento anticipates commencing enrollment of patients in the study in June 2021.
Shares up nearly 2% premarket
Brazilian Health Regulatory Agency authorizes Sorrento's phase 2 COVID-19 trial
May 20, 2021 9:17 AM ETSorrento Therapeutics, Inc. (SRNE)By: Aakash Babu, SA News Editor
Sorrento Therapeutics (NASDAQ:SRNE) announces receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 Pivotal clinical trial of COVI-MSC, an injectable infusion of mesenchymal stem cells, for the treatment of hospitalized COVID-19 patients suffering from ARDS.
The study is expected to enroll 100 patients (33 placebo and 67 treated patients) in three months from the date of first enrollment.
It will compare therapy using mesenchymal stem cells to placebo (and standard of care) in 100 COVID-19 patients hospitalized due to acute respiratory distress syndrome (ARDS).
Sorrento anticipates commencing enrollment of patients in the study in June 2021.
Shares up nearly 2% premarket
(1)
(0)Scroll down for more posts ▼
